All In Biotech

Free tool

FAERS Monitor: Envarsus Xr

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 206406 or its brand name (Envarsus Xr, Tacrolimus). Reports on generic versions are filed under their own applications.

Reports

131,679

Serious

118,245

90% of reports

Hospitalization

52,492

Death reported

20,659

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use13,632
  • drug ineffective9,158
  • product use in unapproved indication6,247
  • drug interaction5,771
  • acute kidney injury5,731
  • diarrhoea4,761
  • transplant rejection4,365
  • cytomegalovirus infection4,225
  • pyrexia3,958
  • covid-193,872
  • toxicity to various agents3,789
  • pneumonia3,755
  • death3,688
  • renal impairment3,039
  • post transplant lymphoproliferative disorder3,003

Reports by year received

View as table
YearReports
2004169
2005219
2006259
2007555
2008951
20091,053
20101,201
20112,205
20122,459
20131,608
20142,523
20153,011
20164,273
20176,324
20189,468
20199,832
202011,792
202111,245
202211,517
202312,900
202414,007
202513,919
202610,189

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,922,480 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
post transplant lymphoproliferative disorderSignal3,003228.1215.8278,744
transplant rejectionSignal4,365189.7181.6373,470
cytomegalovirus infectionSignal4,22554.152.3164,325
acute kidney injurySignal5,7316.26.024,097
drug interactionSignal5,7716.05.823,299
renal impairmentSignal3,0396.05.712,128
product use in unapproved indicationSignal6,2474.14.014,465
toxicity to various agentsSignal3,7893.63.57,175
covid-19Signal3,8723.63.57,105
off label useSignal13,6322.52.512,721
pneumonia3,7551.91.81,505
pyrexia3,9581.81.81,515
diarrhoea4,7611.21.1133
drug ineffective9,1581.11.1107
death3,6880.70.7566

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.